-
International Journal of Chronic Obstructive Pulmonary Disease
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Editorial: COPD: The end of the beginning ||FREE PAPER||
(2242) Views (431) Full article downloads
Authors: Richard Russell, Dave Singh, Irfan Rahman, Alan J Crockett
Published Date April 2006
Volume 2006:1(1) Pages 1 - 1
DOI: http://dx.doi.org/10.2147/COPD.S
Richard Russell1, Dave Singh2, Irfan Rahman3, Alan J Crockett4
1Wexham Park Hospital, Berkshire, UK; 2Manchester University Hospitals Trust, Manchester, UK; 3University of Rochester Medical Center, Rochester, NY, USA; 4Department of General Practice, University of Adelaide, Adelaide, SA, Australia
After the Battle of El Alamein Winston Churchill said “Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning”. This is perhaps an apt quotation to use about the state of knowledge of chronic obstructive pulmonary disease.
Never before has there been so much focus on this common, chronic, and terrible disease, which fills clinics and hospital beds every winter and causes enormous morbidity and increasing mortality. At every level in the healthcare community around the world there is interest in this problem leading to increased research funding and output as well as increasing pressure on governments to legislate against smoking. Global pharmaceutical companies are now investing heavily in target and drug discovery for COPD, and an increasing number of candidate compounds are being tested.
- Journal Indexing
See where all the Dove Press journals are indexed
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Clinical effectiveness of the Respimat® inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices
- Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity
- The pathophysiology of bronchiectasis
- Exacerbation rate, health status and mortality in COPD – a review of potential interventions




